<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492516</url>
  </required_header>
  <id_info>
    <org_study_id>Royan-Nerve-008</org_study_id>
    <nct_id>NCT02492516</nct_id>
  </id_info>
  <brief_title>Intravenous Injection of Adipose Derived Mesenchymal Stem Cell for ALS</brief_title>
  <official_title>Evaluation the Safety of Intravenous Injection of Adipose Derived Mesenchymal Stem Cell in Patients With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royan Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royan Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Amyotrophic lateral sclerosis (ALS) is a lethal degenerative disorder that upper motor and
      lower motor neurons are destroyed in brain stem and spinal cord. Riluzole is the only
      therapeutic option now. Recently several studies have shown that stem cell transplantation is
      safe and can be effective in reduction of disease progression and increase of quality of
      life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      the study is perform with 8 patients who has sporadic form of ALS with(ALS-Functional Rating
      Test) ALS-FRS&gt; 24 and (Forced Vital Capacity) FVC&gt;40% . The adipose sample is provide from
      healthy donors with abdominal lipoaspiration. After isolation and culture of mesenchymal stem
      cells, the cells are injected intravenously (2 million cells/kg). All the patients will be
      followed for 12 months at 72hours, 2months, 4 months, 6 months and 12 months after
      transplantation to find the adverse events. During follow up the assessments including:
      ALS-FRS, FVC and electromyography and serologic tests.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fever</measure>
    <time_frame>72hours</time_frame>
    <description>The increase of body temperature that is defined as fever, within 72 hours after injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unconsciousness</measure>
    <time_frame>72hours</time_frame>
    <description>Evaluation the consciousness state of patients within 72 hours after stem cell injection with clinical examination and GCS score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation the improvement of ALS functional rating scale ( ALS-FRS) by ALS-FRS questionnare, 2 months after cell injection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation the improvement of FVC by spirometry, 2 months after cell injection.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Stem cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients with diagnosis of ALS who receive adipose derived mesenchymal stem cell.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>mesenchymal stem cells</intervention_name>
    <description>mesenchymal stem cells injection via peripheral vein.</description>
    <arm_group_label>Stem cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both gender

          -  Age: 18-55

          -  Sporadic form of disease

          -  ALS-FRS&gt; = 24

          -  FVC &gt;= 40%

        Exclusion Criteria:

          -  Familial form of ALS

          -  Malignancy

          -  Autoimmune disease

          -  Diagnosis of other motor neuron diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamid Gourabi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Head of Royan Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nasser Aghdami, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Head of department of Regenerative Medicine,Royasn Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Masood Nabavi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Professor associated of neurology, Shahed University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leila Arab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Regenerative Medicine, Royan Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royan Institute</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>April 26, 2017</last_update_submitted>
  <last_update_submitted_qc>April 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adipose tissue mesenchymal stem cell intravenous injection ALS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

